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Aim: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover 
molecular details underlying CLL cell genesis. Objects and Methods: The study was conducted on peripheral blood samples of patients 
with CLL using the following methods: RNA isolation, analysis of expression of transcription factors using RT2 profiler assay, 
bioinformatics analysis of publicly available data bases on expression. Results: We have shown that the TGFB — SMAD canonical 
pathway is not active in CLL cells. SMAD-responsive genes, such as BCL2L1 (BCL-XL), CCND2 (Cyclin D2), and MYC, are 
down-regulated in CLL cells compared with peripheral blood B cells of healthy donors. Conclusions: The TGFB-mediated signal-
ing is not active in CLL cells due to low (or absent) expression of SMAD1, -4, -5, -9, and ATF-3. Expression and phosphorylation 
status of SMAD2 and -3 should be further elucidated in the future studies.
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Chronic lymphocytic leukemia (CLL) is represented 
by small B-lymphocytes, accumulating in bone mar-
row, spleen, lymph nodes and other tissues. B-cell 
count in peripheral blood in CLL can reach very high 
numbers, more than 5–10•106/ml [1]. Noteworthy, CLL 
cells express various surface markers, characteristic 
for mature and/or naїve B cells, such as B-cell receptor 
(BCR), CD5, CD19, CD23 antigens, IgM/IgD etc. [2]. 
However, in contrast to normal B cells, CLL cells can not 
be activated. Moreover, they are incapable to differenti-
ate into plasma cells and do not produce antibo dies [3]. 
Therefore, it is widely accepted that CLL cells are im-
munologically incompetent mature B-lymphocytes.
From other hand, CLL cells express a set of cytokine 
receptors, namely interleukin receptors, — IL-2R, -4R, 
-6R, -10R, -13R [4–7], and also receptors for tumor 
necrosis factor alpha (TNFA) [5, 8], interferon alpha 
(INFA) [9] and gamma (INFG) [10] and also for tumor 
growth factor beta (TGFB) [11]. We have to mention, that 
CLL cells, despite being non-proliferating, secrete still 
many cytokines that are described above.
One of the most important cytokines is TGFB, which 
has a dual role in carcinogenesis [12]. In lymphoid cells 
the active canonical TGFB pathway leads to apoptosis. 
Hence, it was shown that activation of the TGFB path-
way resulted in induction of pro-apoptotic BMF, BIM, 
and, as consequence, BAX [13]. In Burkitt’s lymphoma 
cells, anti-apoptotic BCL2L1 (BCLXL) and BCL2 were 
downregulated upon the TGFB-pathway activation [14]. 
However, in CLL cells, levels of BCL2 did not differ from 
normal peripheral blood B cells.
We asked a question, what is the status of the TGFB 
pathway in CLL cells, with the aim to uncover molecular 
details underlying CLL pathogenesis.
MATERIALS AND METHODS
Clinical specimens. Samples of the periph-
eral blood from patients were obtained at the De-
partment of Oncohematology of R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology (IEPOR) of NAS of Ukraine (in the period 
19.11.2014–31.12.2016). The study included 38 pa-
tients. Among them, CLL was diagnosed in 29 individu-
als, 4 persons had CLL of the mixed type, 1 patient had 
B-cell lymphoma, 1 — marginal zone lymphoma and 
3 patients had T-cell lymphoma. The non-CLL cases 
will be analyzed individually in the future studies. The 
main types and cytological variants of lymphoid tumors 
were diagnosed, according to the WHO classification 
[15]. Mononuclear cells were isolated from peripheral 
blood, using centrifugation with the Ficoll-Paque den-
sity gradient media. The cell content was usually high 
(80–99% of B-cells in a population of mononuclear 
cells in patients with CLL).
For control, B lymphocytes were isolated from 
the peripheral blood of 3 healthy donors, using the 
Ficoll-Paque density gradient media to separate mono-
nuclear cells with the following “rosetting” of T-cells 
by erythrocytes of sheep blood.
All experimental work was performed, according 
to the protocols that have been approved by the Com-
mittee on Bioethics at IEPOR. Also, all patients were 
thoroughly informed about the study.
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RNA isolation and cDNA synthesis. CLL cells were 
isolated from peripheral blood of patients by gradient 
centrifugation using the Ficoll-Paque density gradient 
media.
Cells were resuspended in TRIzol reagent 
(GibcoBRL, USA) and stored at −20 °C until further 
use. The total RNA was isolated, using the RNeasy Mini 
Kit (Qiagen Inc., Germany), according to the manu-
facturer’s instructions. The cDNAs were synthesized, 
using 2 μg of total RNA, M-MLV Reverse Transcriptase 
and RNAse inhibitor (Invitrogen, USA), according to the 
manufacturer’s protocol.
Analysis of the transcription factors expression 
using RT2 profiler assay. The expression profile 
of 84 transcription factors was determined in duplets 
using two identical PARN-075Z plates. Along with 
positive and negative controls, a total of 96 genes were 
analyzed. The RNA mixture consisted of 25 μl (a half) 
of each RNA solution isolated from the sample. The 
control represented a mixture of RNAs isolated from 
the peripheral blood B cells of three healthy donors. 
q-PCR was performed, using 2 μg cDNA and the 
SYBR Green Master Mix (Thermo Fisher Scientific 
Inc., USA), on the PCR System 7500 (Applied Bio-
system, USA). CT was not measured after 35 cycles. 
The obtained CT values were downloaded into the 
manufacturer’s website (Thermo Fisher Scientific 
Inc., USA) for the online analysis of the transcription 
factors expression.
Bioinformatic data analysis. In order to analyze 
expression of genes at the mRNA level, a publically 
available data base Oncomine was used. This data 
base contains published data that have been collected, 
standardized, annotated and analyzed by Compendia 
Bioscience (www.oncomine.com, September 2017, 
Thermo Fisher Scientific, Ann-Arbor, MI, USA).
RESULTS AND DISCUSSION
A PARN-075Z platform was used to assess ex-
pression of 84 various transcription factors. A mix-
ture of RNAs isolated from the peripheral blood cells 
of 38 patients was used to perform these experi-
ments, in comparison with the RNAs mixture isolated 
from the peripheral blood B-lymphocytes of three 
healthy individuals. We have shown that the majority 
of TFs were downregulated, in patient mononuclear 
(presumably CLL) cells [16]. For example, both MYC 
and NFkB1 genes were downregulated 3.26 and 
4.23 fold, respectively. We also found that many 
genes, which are usually induced upon activation 
of the IL-2 — STAT5 pathway (Matveeva et al., 2017, 
submitted), were downregulated in CLL cells. We have 
shown that ID1, HIF1A, MCL1, BCL2, BCL2L1, and 
Cyclin D2 (CCND2) genes are expressed in CLL cells 
at lower levels than in B cells of healthy donors. These 
data suggest that the IL-2 — STAT5 pathway is inac-
tivated in CLL cells, probably, due to the lack of STAT 
phosphorylation.
Among other pathways that are crucial for regula-
tion of B cell fate, very important is the TGFB signaling. 
Noteworthy, activation of the TGFB pathway in vitro did 
not lead to increased apoptosis in CLL cells, in contrast 
to the peripheral blood B cells [17]. Moreover, TGFB 
is secreted by CLL cells and could be measured in pa-
tient blood sera. Of note is that the TGFB receptors 
(TGFBR) are expressed at the similar level in CLL cells 
and peripheral blood B-lymphocytes.
It is known that the active TGFB ligand binds to ho-
modimers of receptors, TGFBRI and TGFBRII [12]. 
A tetramer of these receptors is formed then and 
auto-phosphorylated TGFBRII can transfer a phos-
phate group to TGFBRI starting the signal transduction 
through SMAD proteins (Fig. 1 , a, b).
SMADs are homologs of D. melanogaster proteins, 
named Mothers against decapentaplegic (MAD). 
It was shown that mutations in MAD led to repression 
of the gene called Decapentaplegic (Dpp) in a fruit fly 
embryo. Dpp is a morphogen and is responsible for 
correct growth of many tissues in drosophila.
The SMAD protein family consists of at least 
8 members. SMAD1, -2, -3, -5, and -8 are regula-
tory proteins (R-SMADs) that could be phosphory-
lated [18]. SMAD8 is encoded by the SMAD9 gene. 
Importantly, only SMAD2 and SMAD3 function 
as R-SMADs in the canonical TGFB pathway (Fig. 1, c).
SMAD4 (also called co-SMAD) forms the complexes 
with phosphorylated SMAD2 and SMAD3 (Fig. 1, d). 
These heterodimers, containing SMAD4, are imported 
to a nucleus, where they bind to DNA, together with 
Fig. 1. An oversimplified scheme depicting the TGFB pathway. 
The active TGFB ligand binds to homodimers of receptors, TGFBRI 
and TGFBRII (a). A tetramer of these receptors is formed then and 
auto-phosphorylated TGFBRII can transfer a phosphate group 
to TGFBRI (b). SMAD2 and SMAD3 are phosphorylated then (c). 
SMAD4 forms the complexes with the phosphorylated SMAD2 and 
SMAD3 (d). These heterodimers are imported to a nucleus. They bind 
to DNA and transactivate a set of responsive genes (e). SMAD6 and 
SMAD7 can bind to a SMAD-specific E3 ubiquitin ligase SMURF (f). 
Together, they form complexes with TGFBR and that results in pro-
teasomal degradation of the latter (g). The scheme was prepared with 
the help of a ChemOffice® Professional 17 free trial copy
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other co-factors, and transactivate (or, alternatively, 
repress) a set of responsive genes, namely ATF3, ID1, 
CMYC, etc (Fig. 1, e).
SMAD6 and SMAD7 are the inhibitory SMADs 
(I-SMADs). They can bind to a SMAD-specific E3 ubiq-
uitin ligase SMURF (Fig. 1, f). Together, they form 
complexes with TGFBR that results in proteasomal 
degradation of the latter [18] (Fig. 1, g).
Taking into consideration that the TGFB pathway 
might be inactivated in CLL cells, we assessed ex-
pression of several SMADs in CLL cells in comparison 
with the peripheral blood B cells. We have found that 
all the studied SMADs (SMAD1, -4, -5, and -9) were 
downregulated at the mRNA level in CLL in com-
parison with B cells (Fig. 2, a left panel). Noteworthy, 
SMAD1 and SMAD9 were hardly detectable; their 
expression was lower in CLL cells up to 20 folds 
(18.2 and 18.1, respectively). SMAD4 expression was 
diminished 1.6 fold and SMAD5 — 2.8 fold. It is obvi-
ous to conclude that the alternative TGFB pathway, 
where SMAD1, -5, and -6 play an important role, 
could be inactivated due to low expression of these 
regulatory molecules.
To corroborate our results, we have analyzed a set 
of the experimental data that have been published 
earlier and deposited to the Oncomine portal. SMAD1, 
-2, -5, -6, and -9 are expressed at very low levels 
in B cells (Fig. 3). Importantly, their expression at mRNA 
levels diminished further in CLL cells: almost 7 fold 
for SMAD1 [19], 2.5 fold for SMAD2 [20], 2.5 fold for 
SMAD6 [21] and 2 fold for SMAD9 [19]. The SMAD5 lev-
els were similar in B and CLL cells, according to [21].
SMAD3 and SMAD4  showed higher signals 
in B cells, compared with other SMADs, but their levels 
dropped dramatically in CLL cells as well: 6 fold for 
SMAD3 [19] and 2.4 fold for SMAD4 [21]. Importantly, 
these data are in concordance with the obtained in our 
study results. Thus, we were expecting that SMAD 
responsive genes will be not induced.
As was mentioned above, expression of BCL2L1, 
CMYC, and ID1 genes were diminished in CLL cells 
compared with the peripheral blood B cells of healthy 
Fig. 3. Expression levels of SMADs assessed by microarray technique. Note the significant down-regulation of the studied genes 
(indicated by arrows): SMAD1 [19], SMAD2 [20], SMAD3 [19], SMAD4, SMAD5, SMAD6, SMAD7 [21], and SMAD9 [19]. BL — 
Burkitt’s lymphoma; GC — germinal center; DLBCL — diffuse large B-cell lymphoma
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Fig. 2. Relative gene mRNA expression assessed by q-PCR. An ex-
pression study was performed for two RT2 plates. Median values are 
presented here. The standard deviation is no more than 30% of the 
median value. Expression of SMADs is shown on the left panel; 
ATFs — on the middle; TGIF1 — on the right. BL — Burkitt’s lympho-
ma; GC — germinal center; DLBCL — diffuse large B-cell lymphoma
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donors (Matveeva et al., 2017, submitted). Expres-
sion of other SMAD-induced genes were also studied 
(Fig. 2, 4 and 5). Thus, members of a family of activat-
ing transcription factors (ATF), namely ATF3 and ATF4, 
were downregulated in CLL cells: ATF3 — 15.9 fold 
and ATF4 — 1.8 fold. Expression of ATF1 was similar 
in CLL and B cells, and ATF2 was diminished in CLL 
cells; however, the differences were not significant 
(Fig. 2, the middle panel). Importantly, ATF3 should 
be induced by the active TGFB — SMAD pathway. 
ATF3 can bind to SMAD2 and SMAD3, resulting in re-
pression of the ID1 transcription [22]. However, in our 
case, induction of ATF3 was not detected. Moreover, 
the analysis of the Oncomine data base corroborated 
our results (Fig. 4). Thus, the ATF3 expression was 
6 fold (median value) lower in CLL.
No big difference in expression of the TGFB-in-
duced factor (TGIF1) was found in CLL cells (approxi-
mately 2 fold) (Fig. 2, the right panel). TGIF1 encodes 
another co-repressor of the SMAD2/3-dependent 
transcription [23].
Of note, the levels of the TGFB-inducible early 
gene (TIEG, also called KLF10) were downregulated 
dramatically in CLL cells versus normal B cells (Fig. 5). 
Thus, expression was diminished 17 fold comparing 
with the published data [19, 20]. We have to mention 
that overexpression of KLF10 in pancreatic cancer-
ous cells resulted in their apoptosis [24]. Importantly, 
it was shown that expression of KLF10 is quite high 
in spleen and peripheral blood leukocytes compared 
to other tissues [25].
Thereby, many TGFB — SMADs responsive genes 
are not induced in CLL cells. It can be due to the low ex-
pression of SMADs or the lack of their phosphorylation.
CONCLUSIONS
We have found that the TGFB — SMAD2/3 path-
way is not active in CLL cells. Expression of the 
SMAD genes were diminished in CLL cells com-
pared with the peripheral blood B cells. Moreover, 
the TGFB — SMAD-responsive genes, namely 
BCL2L1 (BCL-XL), CCND2 (Cyclin D2), ID1, MYC, 
ATF3, TGIF1, and KLF10 (TIEG), are down-regulated 
in CLL cells as well.
Why the TGFB — SMAD2/3 pathway is inacti-
vated, it is an open question. Beside low expression 
of SMADs, there might be the lack of the SMAD2 and 
SMA3 phosphorylation involved. Expression and 
the phosphorylation status of SMAD2 and -3 should 
be further elucidated in the future studies.
Fig. 4. Expression levels of ATF3 assessed by microarray tech-
nique. Note the significant down-regulation of the ATF3 gene 
(indicated by arrows) in the studies [26] (a), [19] (b), [20] (c), 
and [21] (d). BL — Burkitt’s lymphoma; GC — germinal center; 
DLBCL — diffuse large B-cell lymphoma
Fig. 5. Expression levels of TIEG (KLF10) assessed by microarray technique. Note the significant down-regulation of the 
KLF10 gene (indicated by arrows) in the studies [20] (a), [19] (b), and [21] (c). BL — Burkitt’s lymphoma; GC — germinal center; 
DLBCL — diffuse large B-cell lymphoma
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